REFERENCES
1. Cromm, P. M.; Crews, C. M. Targeted protein degradation: from chemical biology to drug discovery. Cell. Chem. Biol. 2017, 24, 1181-90.
2. Farley, K.; Bhattacharya, S.; Cleland, J.; Chandran, P.; Wu, J. The targeted protein degradation landscape. Nat. Rev. Drug. Discov. 2025, 24, 164-5.
3. Zhang, G.; Yan, S.; Liu, Y.; Du, Z.; Min, Q.; Qin, S. PROTACs coupled with oligonucleotides to tackle the undruggable. Bioanalysis 2025, 17, 261-76.
4. Zhang, C.; Liu, Y.; Li, G.; et al. Targeting the undruggables-the power of protein degraders. Sci. Bull. 2024, 69, 1776-97.
5. Yan, S.; Zhang, G.; Luo, W.; et al. PROTAC technology: From drug development to probe technology for target deconvolution. Eur. J. Med. Chem. 2024, 276, 116725.
6. Yoon, H.; Rutter, J. C.; Li, Y. D.; Ebert, B. L. Induced protein degradation for therapeutics: past, present, and future. J. Clin. Invest. 2024, 134, e175265.
7. Kelm, J. M.; Pandey, D. S.; Malin, E.; et al. PROTAC'ing oncoproteins: targeted protein degradation for cancer therapy. Mol. Cancer. 2023, 22, 62.
8. Qin, S.; Xiao, X. Key advances and application prospects of PROTAC technologies in the next 5 years. Future. Med. Chem. 2025, 17, 987-9.
9. Kim, J.; Byun, I.; Kim, D. Y.; Joh, H.; Kim, H. J.; Lee, M. J. Targeted protein degradation directly engaging lysosomes or proteasomes. Chem. Soc. Rev. 2024, 53, 3253-72.
10. Zhou, Z.; Liang, J.; Cheng, B.; et al. Targeted degradation technologies utilizing autophagy. Int. J. Mol. Sci. 2025, 26, 6576.
11. Xie, H.; Zhang, C. Potential of the nanoplatform and PROTAC interface to achieve targeted protein degradation through the ubiquitin-proteasome system. Eur. J. Med. Chem. 2024, 267, 116168.
12. Gonçalves, A. L.; Cunha, P. M.; da Silva Lima, A.; Dos Santos, J. C.; Segato, F. Production of recombinant lytic polysaccharide monooxygenases and evaluation effect of its addition into Aspergillus fumigatus var. niveus cocktail for sugarcane bagasse saccharification. Biochim. Biophys. Acta. Proteins. Proteom. 2023, 1871, 140919.
13. Price, E.; Weinheimer, M.; Rivkin, A.; et al. Beyond rule of five and PROTACs in modern drug discovery: polarity reducers, chameleonicity, and the evolving physicochemical landscape. J. Med. Chem. 2024, 67, 5683-98.
14. Pike, A.; Williamson, B.; Harlfinger, S.; Martin, S.; McGinnity, D. F. Optimising proteolysis-targeting chimeras (PROTACs) for oral drug delivery: a drug metabolism and pharmacokinetics perspective. Drug. Discov. Today. 2020, 25, 1793-800.
15. Shi, J.; Wang, L.; Zeng, X.; et al. Precision-engineered PROTACs minimize off-tissue effects in cancer therapy. Front. Mol. Biosci. 2024, 11, 1505255.
16. Syahputra, E. W.; Lee, H.; Cho, H.; Park, H. J.; Park, K. S.; Hwang, D. PROTAC delivery strategies for overcoming physicochemical properties and physiological barriers in targeted protein degradation. Pharmaceutics 2025, 17, 501.
17. Toriki, E. S.; Papatzimas, J. W.; Nishikawa, K.; et al. Rational chemical design of molecular glue degraders. ACS. Cent. Sci. 2023, 9, 915-26.
18. Stanton, C.; Nutsch, K.; Bollong, M. J. Stressing out with electrophiles. Nat. Chem. Biol. 2025, 21, 612-3.
19. Zhang, X. J.; Chen, S.; Huang, K. X.; Le, W. D. Why should autophagic flux be assessed? Acta. Pharmacol. Sin. 2013, 34, 595-9.
20. Wu, Y.; Lin, B.; Lu, Y.; et al. Aptamer-LYTACs for targeted degradation of extracellular and membrane proteins. Angew. Chem. Int. Ed. 2023, 62, e202218106.
21. Mikitiuk, M.; Barczyński, J.; Bielski, P.; et al. IGF2 peptide-based LYTACs for targeted degradation of extracellular and transmembrane proteins. Molecules 2023, 28, 7519.
22. Mu, X.; Mu, C.; Wang, M.; Meng, C.; Liu, H.; Lu, H. Nanotechnology advances proteolysis targeting chimeras (PROTACs): transition from basic research to clinical application. Int. J. Nanomedicine. 2025, 20, 12177-98.
23. Peer, D.; Karp, J. M.; Hong, S.; Farokhzad, O. C.; Margalit, R.; Langer, R. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2007, 2, 751-60.
24. Mitchell, M. J.; Billingsley, M. M.; Haley, R. M.; Wechsler, M. E.; Peppas, N. A.; Langer, R. Engineering precision nanoparticles for drug delivery. Nat. Rev. Drug. Discov. 2021, 20, 101-24.
25. Wilhelm, S.; Tavares, A. J.; Dai, Q.; et al. Analysis of nanoparticle delivery to tumours. Nat. Rev. Mater. 2016, 1, 16014.
26. Rodriguez‐abetxuko, A.; Romero‐ben, E.; Ontoria, A.; et al. Engineered metal‐loaded biohybrids to promote the attachment and electron‐shuttling between enzymes and carbon electrodes. Adv. Funct. Mater. 2024, 34, 2400479.
27. Zhong, J.; Zhao, R.; Wang, Y.; Su, Y. X.; Lan, X. Nano-PROTACs: state of the art and perspectives. Nanoscale 2024, 16, 4378-91.
28. Kim, J.; Cho, H.; Lim, D. K.; Joo, M. K.; Kim, K. Perspectives for improving the tumor targeting of nanomedicine via the EPR Effect in clinical tumors. Int. J. Mol. Sci. 2023, 24, 10082.
29. Sun, J.; Gu, M.; Peng, L.; et al. A Self-assembled nano-molecular glue (Nano-mGlu) enables GSH/H2O2-triggered targeted protein degradation in cancer therapy. J. Am. Chem. Soc. 2025, 147, 372-83.
30. Xu, M.; Chen, J.; Wang, S.; et al. Autophagy-activating nanoautophagosome-tethering compounds for targeted protein degradation specifically in tumor cells. ACS. Macro. Lett. 2025, 14, 250-7.
31. Xing, Y.; Li, J.; Wang, L.; et al. A bifunctional lysosome-targeting chimera nanoplatform for tumor-selective protein degradation and enhanced cancer immunotherapy. Adv. Mater. 2025, 37, e2417942.
32. Zhong, G.; Chang, X.; Xie, W.; Zhou, X. Targeted protein degradation: advances in drug discovery and clinical practice. Signal. Transduct. Target. Ther. 2024, 9, 308.
33. Kashyap, D.; Milne, T.; Booth, M. DNA-programmable protein degradation: dynamic control of PROTAC activity via DNA hybridization and strand displacement. ChemRxiv. 2025.
34. Torres, J.; Valenzuela Oses, J. K.; Rabasco-Álvarez, A. M.; González-Rodríguez, M. L.; García, M. C. Innovations in cancer therapy: endogenous stimuli-responsive liposomes as advanced nanocarriers. Pharmaceutics 2025, 17, 245.
35. Thomas, R. G.; Surendran, S. P.; Jeong, Y. Y. Tumor microenvironment-stimuli responsive nanoparticles for anticancer therapy. Front. Mol. Biosci. 2020, 7, 610533.
37. Sahay, G.; Alakhova, D. Y.; Kabanov, A. V. Endocytosis of nanomedicines. J. Control. Release. 2010, 145, 182-95.
38. Li, L. M.; Xie, Y. P.; Qin, Y. R.; et al. Tumor microenvironment‐responsive drug self‐delivery systems to treat cancer and overcome MDR. Rare. Metals. 2024, 44, 1-33.
39. Liu, Y.; Si, L.; Jiang, Y.; et al. Design of pH-responsive nanomaterials based on the tumor microenvironment. Int. J. Nanomedicine. 2025, 20, 705-21.
40. Pei, D.; Buyanova, M. Overcoming endosomal entrapment in drug delivery. Bioconjugate. Chem. 2019, 30, 273-83.
41. Varkouhi, A. K.; Scholte, M.; Storm, G.; Haisma, H. J. Endosomal escape pathways for delivery of biologicals. J. Control. Release. 2011, 151, 220-8.
42. Huh, K. M.; Kang, H. C.; Lee, Y. J.; Bae, Y. H. pH-sensitive polymers for drug delivery. Macromol. Res. 2012, 20, 224-33.
43. Akinc, A.; Thomas, M.; Klibanov, A. M.; Langer, R. Exploring polyethylenimine-mediated DNA transfection and the proton sponge hypothesis. J. Gene. Med. 2005, 7, 657-63.
44. Shin, Y.; Husni, P.; Kang, K.; et al. Recent advances in pH- or/and photo-responsive nanovehicles. Pharmaceutics 2021, 13, 725.
45. Kanamala, M.; Wilson, W. R.; Yang, M.; Palmer, B. D.; Wu, Z. Mechanisms and biomaterials in pH-responsive tumour targeted drug delivery: a review. Biomaterials 2016, 85, 152-67.
46. Huang, L.; Sun, X.; Zuo, Q.; et al. A pH-responsive PROTAC-based nanosystem triggers tumor-specific ferroptosis to construct in situ tumor vaccines. Mater. Today. Bio. 2025, 31, 101523.
47. Blanco, E.; Shen, H.; Ferrari, M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat. Biotechnol. 2015, 33, 941-51.
48. Du, J.; Lane, L. A.; Nie, S. Stimuli-responsive nanoparticles for targeting the tumor microenvironment. J. Control. Release. 2015, 219, 205-14.
49. Cui, M.; Zhang, D.; Zheng, X.; et al. Intelligent modular DNA lysosome-targeting chimera nanodevice for precision tumor therapy. J. Am. Chem. Soc. 2024, 146, 29609-20.
50. Min, H.; Sun, M. C.; Hu, K.; et al. Ionizable nano-PROTAC overcomes endosomal entrapment for enhanced LRG1 degradation and tumor suppression. Angew. Chem. Int. Ed. 2026, 65, e20235.
51. Kessenbrock, K.; Plaks, V.; Werb, Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 2010, 141, 52-67.
52. Wang, H. X.; Yang, X. Z.; Sun, C. Y.; Mao, C. Q.; Zhu, Y. H.; Wang, J. Matrix metalloproteinase 2-responsive micelle for siRNA delivery. Biomaterials 2014, 35, 7622-34.
53. Pang, Q.; Xu, Z.; Sun, T.; et al. Strategic chemical synthesis and application of nanocarriers responsive to the tumor microenvironment. Nano. Today. 2024, 58, 102421.
54. Kim, D.; Yang, G.; Lim, C.; et al. Cancer specific CAIX-targeting supramolecular lysosome-targeting chimeras (Supra-LYTAC) for targeted protein degradation. Adv. Sci. 2025, 12, e2503134.
55. Kapalatiya, H.; Madav, Y.; Tambe, V. S.; Wairkar, S. Enzyme-responsive smart nanocarriers for targeted chemotherapy: an overview. Drug. Deliv. Transl. Res. 2022, 12, 1293-305.
56. Tong, F.; Wang, Y.; Xu, Y.; et al. MMP-2-triggered, mitochondria-targeted PROTAC-PDT therapy of breast cancer and brain metastases inhibition. Nat. Commun. 2024, 15, 10382.
57. Song, C.; Jiao, Z.; Hou, Z.; et al. Selective protein of interest degradation through the split-and-mix liposome proteolysis targeting chimera approach. J. Am. Chem. Soc. 2023, 145, 21860-70.
58. Yang, F.; Luo, Q.; Wang, Y.; et al. Targeted biomolecule regulation platform: a split-and-mix PROTAC approach. J. Am. Chem. Soc. 2023, 145, 7879-87.
59. Zhou, Z.; Ni, K.; Deng, H.; Chen, X. Dancing with reactive oxygen species generation and elimination in nanotheranostics for disease treatment. Adv. Drug. Delivery. Rev. 2020, 158, 73-90.
60. Yang, B.; Chen, Y.; Shi, J. Reactive oxygen species (ROS)-based nanomedicine. Chem. Rev. 2019, 119, 4881-985.
61. Zhao, C.; Chen, J.; Zhong, R.; Chen, D. S.; Shi, J.; Song, J. Oxidative-species-selective materials for diagnostic and therapeutic applications. Angew. Chem. Int. Ed. 2021, 60, 9804-27.
62. Ye, H.; Zhou, Y.; Liu, X.; et al. Recent advances on reactive oxygen species-responsive delivery and diagnosis system. Biomacromolecules 2019, 20, 2441-63.
63. Lee, M. H.; Yang, Z.; Lim, C. W.; et al. Disulfide-cleavage-triggered chemosensors and their biological applications. Chem. Rev. 2013, 113, 5071-109.
64. Lv, H.; Zhen, C.; Liu, J.; Yang, P.; Hu, L.; Shang, P. Unraveling the potential role of glutathione in multiple forms of cell death in cancer therapy. Oxid. Med. Cell. Longev. 2019, 2019, 3150145.
65. Liu, H.; Ren, C.; Sun, R.; et al. Reactive oxygen species-responsive Pre-PROTAC for tumor-specific protein degradation. Chem. Commun. 2022, 58, 10072-5.
66. Bi, T.; Liang, P.; Zhao, Q.; et al. Targeted degradation of bromodomain-containing protein 4 enabled by reactive oxygen species-activatable NanoPROTACs as an efficient strategy to reverse liver fibrosis in chronic liver injury. J. Med. Chem. 2025, 68, 6328-38.
67. Yao, Q.; Wu, Z.; Li, J.; et al. Reactive oxygen species-instructed supramolecular assemblies enable bioorthogonally activatable protein degradation for pancreatic cancer. J. Am. Chem. Soc. 2025, 147, 18208-18.
68. Liu, H. J.; Chen, W.; Wu, G.; et al. Glutathione-scavenging nanoparticle-mediated PROTACs delivery for targeted protein degradation and amplified antitumor effects. Adv. Sci. 2023, 10, e2207439.
69. Lin, J. Y.; Wu, Y.; Liang, X. H.; et al. A self-assembling LYTAC mediates CTGF degradation and remodels inflammatory tumor microenvironment for triple-negative breast cancer therapy. Adv. Sci. 2025, 12, e2500311.
70. Saravanakumar, G.; Kim, J.; Kim, W. J. Reactive-oxygen-species-responsive drug delivery systems: promises and challenges. Adv. Sci. 2017, 4, 1600124.
72. Xie, F.; Wang, M.; Chen, Q.; et al. Endogenous stimuli-responsive nanoparticles for cancer therapy: from bench to bedside. Pharmacol. Res. 2022, 186, 106522.
73. Gao, J.; Yang, L.; Lei, S.; et al. Stimuli-activatable PROTACs for precise protein degradation and cancer therapy. Sci. Bull. 2023, 68, 1069-85.
74. Zhu, M.; Wang, X.; Zhou, Y.; et al. Breast tumor‐targeted drug delivery via polymer nanocarriers: endogenous and exogenous strategies. J. Appl. Polym. Sci. 2023, 140, e54227.
75. Wang, N.; Cong, W.; Zhu, Y.; et al. Spatiotemporally controlled protein degradation via NIR-activatable PROTAC platform. Sci. China. Chem. 2025, 68, 6621-7.
76. Sheng, J.; Ma, T.; Wu, Y.; Wang, M. Programmable PROTAC delivery for precise and spatiotemporal protein degradation. Chem. Commun. 2026, 62, 2414-27.
77. Hu, H.; Busa, P.; Zhao, Y.; Zhao, C. Externally triggered drug delivery systems. Smart. Mater. Med. 2024, 5, 386-408.
78. Mura, S.; Nicolas, J.; Couvreur, P. Stimuli-responsive nanocarriers for drug delivery. Nat. Mater. 2013, 12, 991-1003.
79. Liu, X.; He, F.; Liu, M. New opportunities of stimulus-responsive smart nanocarriers in cancer therapy. Nano. Mater. Sci. 2024.
80. Cheng, L.; Wang, C.; Feng, L.; Yang, K.; Liu, Z. Functional nanomaterials for phototherapies of cancer. Chem. Rev. 2014, 114, 10869-939.
81. Zhang, L.; Wang, D.; Yang, K.; et al. Mitochondria-targeted artificial “Nano-RBCs” for amplified synergistic cancer phototherapy by a single NIR irradiation. Adv. Sci. 2018, 5, 1800049.
82. Castano, A. P.; Mroz, P.; Hamblin, M. R. Photodynamic therapy and anti-tumour immunity. Nat. Rev. Cancer. 2006, 6, 535-45.
83. Sun, B.; Bte Rahmat, J. N.; Zhang, Y. Advanced techniques for performing photodynamic therapy in deep-seated tissues. Biomaterials 2022, 291, 121875.
84. Li, J.; Pu, K. Semiconducting polymer nanomaterials as near-infrared photoactivatable protherapeutics for cancer. Acc. Chem. Res. 2020, 53, 752-62.
85. Mouret, S.; Baudouin, C.; Charveron, M.; Favier, A.; Cadet, J.; Douki, T. Cyclobutane pyrimidine dimers are predominant DNA lesions in whole human skin exposed to UVA radiation. Proc. Natl. Acad. Sci. U. S. A. 2006, 103, 13765-70.
86. Zhan, J.; Li, X.; Mu, Y.; Yao, H.; Zhu, J. J.; Zhang, J. A photoactivatable upconverting nanodevice boosts the lysosomal escape of PROTAC degraders for enhanced combination therapy. Biomater. Sci. 2024, 12, 3686-99.
87. He, Q.; Zhou, L.; Yu, D.; et al. Near-infrared-activatable PROTAC nanocages for controllable target protein degradation and on-demand antitumor therapy. J. Med. Chem. 2023, 66, 10458-72.
88. Liu, J.; Chen, H.; Ma, L.; et al. Light-induced control of protein destruction by opto-PROTAC. Sci. Adv. 2020, 6, eaay5154.
89. Wang, W.; Zhu, C.; Zhang, B.; Feng, Y.; Zhang, Y.; Li, J. Self-assembled nano-PROTAC enables near-infrared photodynamic proteolysis for cancer therapy. J. Am. Chem. Soc. 2023, 145, 16642-9.
90. Lu, X.; Wang, X.; Liao, H.; Sha, B.; Zhang, Y.; Li, J. Tandem-activatable PROTAC prodrug for tumor biomarker-driven near-infrared opto-proteolysis. Angew. Chem. Int. Ed. 2025, 64, e202510641.
91. Li, J.; Luo, Y.; Zeng, Z.; et al. Precision cancer sono-immunotherapy using deep-tissue activatable semiconducting polymer immunomodulatory nanoparticles. Nat. Commun. 2022, 13, 4032.
92. Huang, P.; Qian, X.; Chen, Y.; et al. Metalloporphyrin-encapsulated biodegradable nanosystems for highly efficient magnetic resonance imaging-guided sonodynamic cancer therapy. J. Am. Chem. Soc. 2017, 139, 1275-84.
93. Ouyang, J.; Tang, Z.; Farokhzad, N.; et al. Ultrasound mediated therapy: recent progress and challenges in nanoscience. Nano. Today. 2020, 35, 100949.
94. Xu, M.; Hu, Y.; Wu, J.; Liu, J.; Pu, K. Sonodynamic nano-LYTACs reverse tumor immunosuppressive microenvironment for cancer immunotherapy. J. Am. Chem. Soc. 2024, 146, 34669-80.
95. Zhang, Q.; Bao, C.; Cai, X.; et al. Sonodynamic therapy-assisted immunotherapy: a novel modality for cancer treatment. Cancer. Sci. 2018, 109, 1330-45.
96. Canavese, G.; Ancona, A.; Racca, L.; et al. Nanoparticle-assisted ultrasound: a special focus on sonodynamic therapy against cancer. Chem. Eng. J. 2018, 340, 155-72.
97. Fan, X.; Jiao, G.; Zhao, W.; Jin, P.; Li, X. Magnetic Fe3O4-graphene composites as targeted drug nanocarriers for pH-activated release. Nanoscale 2013, 5, 1143-52.
98. Najafi, N.; Kheirollah, J.; Majidi, H.; et al. Enhancing magnetic drug targeting efficiency through computational analysis: Investigating Particle-RBC interaction and non-newtonian blood behavior. J. Magn. Magn. Mater. 2024, 600, 172153.
99. Jiao, W.; Dai, L.; Yan, B.; Lyu, Y.; Fan, H.; Liu, X. Heating up the immune battle: magnetic hyperthermia against cancer. Fundam. Res. 2025, 5, 2401-5.
100. Lapusan, R.; Borlan, R.; Focsan, M. Advancing MRI with magnetic nanoparticles: a comprehensive review of translational research and clinical trials. Nanoscale. Adv. 2024, 6, 2234-59.
101. Lv, J.; Yue, R.; Liu, H.; et al. Enzyme-activated nanomaterials for MR imaging and tumor therapy. Coord. Chem. Rev. 2024, 510, 215842.
102. Salahpour Anarjan, F. Active targeting drug delivery nanocarriers: ligands. Nano-Struct. Nano-Objects. 2019, 19, 100370.
103. Chen, Z.; Kankala, R. K.; Long, L.; Xie, S.; Chen, A.; Zou, L. Current understanding of passive and active targeting nanomedicines to enhance tumor accumulation. Coord. Chem. Rev. 2023, 481, 215051.
104. Huang, L.; Zhang, Q.; Long, J.; Liu, Z.; Sun, X. Construction of novel magnetic systems for cancer immunotherapy via cancer-immunity cycle circuits. J. Control. Release. 2025, 378, 38-59.
105. Zhang, H.; Wang, J.; Han, R.; Sun, B.; Luo, C. Bioorthogonal chemistry-driven anticancer nanotherapeutics. Trends. Chem. 2023, 5, 697-710.
106. Keppel, P.; Hecko, S.; Mikula, H. Click-triggered bioorthogonal bond-cleavage reactions. Top. Curr. Chem. 2025, 383, 25.
107. Oliveira, B. L.; Guo, Z.; Bernardes, G. J. L. Inverse electron demand Diels-Alder reactions in chemical biology. Chem. Soc. Rev. 2017, 46, 4895-950.
108. Huang, J.; Yao, Z.; Li, B.; Ping, Y. Targeted delivery of PROTAC-based prodrug activated by bond-cleavage bioorthogonal chemistry for microneedle-assisted cancer therapy. J. Control. Release. 2023, 361, 270-9.
109. Sletten, E. M.; Bertozzi, C. R. Bioorthogonal chemistry: fishing for selectivity in a sea of functionality. Angew. Chem. Int. Ed. 2009, 48, 6974-98.
110. Blackman, M. L.; Royzen, M.; Fox, J. M. Tetrazine ligation: fast bioconjugation based on inverse-electron-demand Diels-Alder reactivity. J. Am. Chem. Soc. 2008, 130, 13518-9.
111. Xie, S.; Zhu, J.; Peng, Y.; et al. In vivo self-assembly of PROTACs by bioorthogonal chemistry for precision cancer therapy. Angew. Chem. Int. Ed. 2025, 64, e202421713.
112. Gao, J.; Hou, B.; Zhu, Q.; et al. Engineered bioorthogonal POLY-PROTAC nanoparticles for tumour-specific protein degradation and precise cancer therapy. Nat. Commun. 2022, 13, 4318.
113. Sun, C.; Liu, S.; Lau, J. W.; Yang, H.; Chen, Y.; Xing, B. Inside Front Cover: Enzyme‐activated orthogonal proteolysis chimeras for tumor microenvironment‐responsive immunomodulation (Angew. Chem. Int. Ed. 22/2025). Angew. Chem. Int. Ed. 2025, 64, e202510013.
114. Swetha, K. L.; Roy, A. Tumor heterogeneity and nanoparticle-mediated tumor targeting: the importance of delivery system personalization. Drug. Deliv. Transl. Res. 2018, 8, 1508-26.
115. Li, S.; Zeng, Q.; Zhu, S.; et al. Engineering nano-PROTAC platforms: Self-assembly, stimuli-responsiveness, and targeted delivery for precision therapy. Chem. Eng. J. 2026, 531, 174085.
116. Zhou, T.; Gao, Y.; Ma, B.; et al. Multi-stimuli activated PROTAC prodrug for controlled protein degradation with enhanced therapeutic effects. Eur. J. Med. Chem. 2026, 306, 118571.
117. Shang, Y.; Zhu, L.; Xiao, Y.; et al. Logic gate activated lysosome targeting DNA nanodevice for controlled proteins degradation. Adv. Funct. Mater. 2023, 34, 2311722.
118. Weng, Z.; Yu, J.; Liao, Y.; Zhang, Y.; Chen, C.; Chen, W. Emerging strategies in smart nano-PROTAC for stimuli-responsive protein degradation and precision cancer therapy. Nano. Biomed. Eng. 2025, 17, 315-32.
119. Cai, J.; Chen, C.; Wang, J.; et al. PROTAC: a revolutionary technology propelling small molecule drugs into the next golden age. Front. Oncol. 2025, 15, 1676414.
120. Majumder, J.; Minko, T. Multifunctional and stimuli-responsive nanocarriers for targeted therapeutic delivery. Expert. Opin. Drug. Deliv. 2021, 18, 205-27.
121. Zhou, W.; Jia, Y.; Liu, Y.; Chen, Y.; Zhao, P. Tumor microenvironment-based stimuli-responsive nanoparticles for controlled release of drugs in cancer therapy. Pharmaceutics 2022, 14, 2346.
122. Hu, F.; Huang, J.; Bing, T.; et al. Stimulus-responsive copper complex nanoparticles induce cuproptosis for augmented cancer immunotherapy. Adv. Sci. 2024, 11, e2309388.
123. Poyia, F.; Neophytou, C. M.; Christodoulou, M. I.; Papageorgis, P. The role of tumor microenvironment in pancreatic cancer immunotherapy: current status and future perspectives. Int. J. Mol. Sci. 2024, 25, 9555.
124. Yang, L.; Yang, Y.; Zhang, J.; et al. Sequential responsive nano-PROTACs for precise intracellular delivery and enhanced degradation efficacy in colorectal cancer therapy. Signal. Transduct. Target. Ther. 2024, 9, 275.
125. Guan, X.; Xu, X.; Tao, Y.; et al. Dual targeting and bioresponsive nano-PROTAC induced precise and effective lung cancer therapy. J. Nanobiotechnol. 2024, 22, 692.
126. Zhang, H. T.; Peng, R.; Chen, S.; et al. Versatile nano-PROTAC-induced epigenetic reader degradation for efficient lung cancer therapy. Adv. Sci. 2022, 9, e2202039.
127. Wang, Y.; Yao, X.; Lu, Y.; et al. A PROTAC-based cuproptosis sensitizer in lung cancer therapy. Adv. Mater. 2025, 37, e2501435.
128. Mi, P. Stimuli-responsive nanocarriers for drug delivery, tumor imaging, therapy and theranostics. Theranostics 2020, 10, 4557-88.
129. Wang, L.; Li, J.; Zeng, X.; et al. Exogenous/endogenous stimuli-responsive antitumor prodrugs advance precision chemotherapy. Bioorg. Med. Chem. 2026, 132, 118485.
130. Park, B.; Choi, J.; Lee, J. H.; et al. Reprogramming of cancer metabolism via photoresponsive nano-PROTAC enhances pyroptosis-mediated immunotherapy. Signal. Transduct. Target. Ther. 2025, 10, 310.
131. Choi, J.; Park, B.; Park, J. Y.; et al. Light-Triggered PROTAC nanoassemblies for photodynamic IDO proteolysis in cancer immunotherapy. Adv. Mater. 2024, 36, e2405475.
132. Zhang, C.; Zeng, Z.; Cui, D.; et al. Semiconducting polymer nano-PROTACs for activatable photo-immunometabolic cancer therapy. Nat. Commun. 2021, 12, 2934.
133. Fu, Z.; Yang, C.; Yang, Y.; Pan, M.; Hou, H.; Li, J. Photodynamic enhancement of PROTAC prodrug activation in hypoxic tumors. Acta. Pharm. Sin. B. 2025, 15, 4945-60.
134. Li, Z.; Ren, G.; Wang, X.; et al. Tumor microenvironment responsive nano-PROTAC for BRD4 degradation enhanced cancer photo-immunotherapy. Biomaterials 2025, 322, 123387.
135. Lu, S.; Shi, Z.; Ding, C.; et al. BRD4-targeted photodegradation nanoplatform for light activatable melanoma therapy. Biomaterials 2025, 317, 123101.
136. Gao, J.; Jiang, X.; Lei, S.; et al. A region-confined PROTAC nanoplatform for spatiotemporally tunable protein degradation and enhanced cancer therapy. Nat. Commun. 2024, 15, 6608.
137. Liu, Y.; Wang, H.; Ding, M.; et al. Ultrasound-activated PROTAC prodrugs overcome immunosuppression to actuate efficient deep-tissue sono-immunotherapy in orthotopic pancreatic tumor mouse models. Nano. Lett. 2024, 24, 8741-51.
138. Chen, S.; Chen, E.; Su, J.; et al. Magnetically navigated nano-PROTAC ameliorates acute lung injury. J. Nanobiotechnol. 2025, 23, 622.
139. Dey, K.; Erwin, N.; Molina, N.; Chen, H.; He, M.; Zheng, G. Nano-TPD: Using nanoparticle-based systems to improve the delivery and therapeutic effect of targeted protein degraders. Med. Chem. Res. 2025, 34, 2205-27.
140. Zeng, S.; Zhang, H.; Shen, Z.; Huang, W. Photopharmacology of proteolysis-targeting chimeras: a new frontier for drug discovery. Front. Chem. 2021, 9, 639176.
141. Wang, Z. W.; Liu, Y.; Zhu, X. PhotoPROTACs: a novel biotechnology for cancer treatment. Trends. Cell. Biol. 2020, 30, 749-51.
142. Zhang, W.; Li, S.; Yuan, H.; Zhao, J. Advances in light-activated PROTACs and phototherapy-combined approaches for cancer treatment. Eur. J. Med. Chem. 2026, 302, 118310.
143. Hua, S.; de Matos, M. B. C.; Metselaar, J. M.; Storm, G. Current trends and challenges in the clinical translation of nanoparticulate nanomedicines: pathways for translational development and commercialization. Front. Pharmacol. 2018, 9, 790.
144. Baker, A. G.; Ho, A. P. T.; Itzhaki, L. S.; Fruk, L. Nanoparticle-mediated targeted protein degradation: an emerging therapeutics technology. Angew. Chem. Int. Ed. 2025, 64, e202503958.
145. Agrahari, V.; Agrahari, V. Facilitating the translation of nanomedicines to a clinical product: challenges and opportunities. Drug. Discov. Today. 2018, 23, 974-91.
146. Joyce, P.; Allen, C. J.; Alonso, M. J.; et al. A translational framework to DELIVER nanomedicines to the clinic. Nat. Nanotechnol. 2024, 19, 1597-611.
147. Sun, T.; Jiang, C. Stimuli-responsive drug delivery systems triggered by intracellular or subcellular microenvironments. Adv. Drug. Delivery. Rev. 2023, 196, 114773.
148. Hao, J.; Li, Y.; Huang, L.; et al. Smart nanoarchitectures for precision RNA delivery: harnessing endogenous and exogenous stimuli in cancer treatment. Theranostics 2025, 15, 7747-78.
149. Cabral, H.; Li, J.; Miyata, K.; Kataoka, K. Controlling the biodistribution and clearance of nanomedicines. Nat. Rev. Bioeng. 2023, 2, 214-32.
150. Fu, F.; Crespy, D.; Landfester, K.; Jiang, S. In situ characterization techniques of protein corona around nanomaterials. Chem. Soc. Rev. 2024, 53, 10827-51.
151. Ly, P.; Ly, K.; Phan, H.; Nguyen, H. H. T.; Duong, V.; Nguyen, H. V. Recent advances in surface decoration of nanoparticles in drug delivery. Front. Nanotechnol. 2024, 6, 1456939.
152. Zhang, Q.; Kuang, G.; Li, W.; Wang, J.; Ren, H.; Zhao, Y. Stimuli-responsive gene delivery nanocarriers for cancer therapy. NanoMicro. Lett. 2023, 15, 44.
153. Wan, J.; Huang, L.; Cheng, J.; Qi, H.; Jin, J.; Wang, H. Balancing the stability and drug activation in adaptive nanoparticles potentiates chemotherapy in multidrug-resistant cancer. Theranostics 2021, 11, 4137-54.
154. Chen, Z.; Li, H.; Bian, Y.; et al. Bioorthogonal catalytic patch. Nat. Nanotechnol. 2021, 16, 933-41.
155. Li, Y.; Vulpe, C.; Lammers, T.; Pallares, R. M. Assessing inorganic nanoparticle toxicity through omics approaches. Nanoscale 2024, 16, 15928-45.
156. Carter, P. J.; Quarmby, V. Immunogenicity risk assessment and mitigation for engineered antibody and protein therapeutics. Nat. Rev. Drug. Discov. 2024, 23, 898-913.
157. Mohamed, M.; Abu Lila, A. S.; Shimizu, T.; et al. PEGylated liposomes: immunological responses. Sci. Technol. Adv. Mater. 2019, 20, 710-24.
158. Miao, G.; He, Y.; Lai, K.; et al. Accelerated blood clearance of PEGylated nanoparticles induced by PEG-based pharmaceutical excipients. J. Control. Release. 2023, 363, 12-26.
159. Gaballa, S. A.; Shimizu, T.; Ando, H.; et al. Treatment-induced and pre-existing anti-peg antibodies: prevalence, clinical implications, and future perspectives. J. Pharm. Sci. 2024, 113, 555-78.
160. Szebeni, J. Complement activation-related pseudoallergy caused by liposomes, micellar carriers of intravenous drugs, and radiocontrast agents. Crit. Rev. Ther. Drug. Carrier. Syst. 2001, 18, 40.
161. Saxena, S.; Sharma, S.; Kumar, G.; Thakur, S. Unravelling the complexity of CARPA: a review of emerging advancements in therapeutic strategies. Arch. Dermatol. Res. 2025, 317, 439.
162. Szebeni, J. Complement activation-related pseudoallergy: a stress reaction in blood triggered by nanomedicines and biologicals. Mol. Immunol. 2014, 61, 163-73.
163. Liu, X.; Zhang, Y.; Ward, L. D.; et al. A proteomic platform to identify off-target proteins associated with therapeutic modalities that induce protein degradation or gene silencing. Sci. Rep. 2021, 11, 15856.
164. Đorđević, S.; Gonzalez, M. M.; Conejos-Sánchez, I.; et al. Current hurdles to the translation of nanomedicines from bench to the clinic. Drug. Deliv. Transl. Res. 2022, 12, 500-25.
165. Wu, X.; Shu, Y.; Zheng, Y.; et al. Recent advances in nanomedicine: cutting-edge research on nano-PROTAC delivery systems for cancer therapy. Pharmaceutics 2025, 17, 1037.
166. Jayaraj, S.; Jiang, W.; Mudalige, T. An Automated capillary electrophoresis based method for drug release profiling of liposomal doxorubicin. J. Pharm. Sci. 2024, 113, 1088-93.
167. Overchuk, M.; Weersink, R. A.; Wilson, B. C.; Zheng, G. Photodynamic and photothermal therapies: synergy opportunities for nanomedicine. ACS. Nano. 2023, 17, 7979-8003.
168. Li, X.; Lovell, J. F.; Yoon, J.; Chen, X. Clinical development and potential of photothermal and photodynamic therapies for cancer. Nat. Rev. Clin. Oncol. 2020, 17, 657-74.
169. Reis, M. E.; Bettencourt, A.; Ribeiro, H. M. The regulatory challenges of innovative customized combination products. Front. Med. 2022, 9, 821094.
170. Li, H.; Shen, X.; Chu, Y.; Yuan, P.; Shuai, Q. Challenging and new opportunities for prodrug technology. Investig. New. Drugs. 2025, 43, 365-76.
171. Gupta, D. K.; Tiwari, A.; Yadav, Y.; Soni, P.; Joshi, M. Ensuring safety and efficacy in combination products: regulatory challenges and best practices. Front. Med. Technol. 2024, 6, 1377443.
172. Arenas-Moreira, M.; Ocaña, A.; Bravo, I.; Alonso-Moreno, C. PROTAC delivery systems: innovative approaches for cancer treatment. Biomed. Pharmacother. 2026, 194, 118892.
173. Wang, C.; Zhang, Y.; Chen, W.; Wu, Y.; Xing, D. New-generation advanced PROTACs as potential therapeutic agents in cancer therapy. Mol. Cancer. 2024, 23, 110.
174. Grasso, G.; Colella, F.; Forciniti, S.; et al. Fluorescent nano- and microparticles for sensing cellular microenvironment: past, present and future applications. Nanoscale. Adv. 2023, 5, 4311-36.
175. Sabit, H.; Pawlik, T. M.; Radwan, F.; et al. Precision nanomedicine: navigating the tumor microenvironment for enhanced cancer immunotherapy and targeted drug delivery. Mol. Cancer. 2025, 24, 160.
176. Mao, Y.; Xie, J.; Yang, F.; Luo, Y.; Du, J.; Xiang, H. Advances and prospects of precision nanomedicine in personalized tumor theranostics. Front. Cell. Dev. Biol. 2024, 12, 1514399.
177. Luo, C.; He, L.; Chen, F.; et al. Stimulus-responsive nanomaterials containing logic gates for biomedical applications. Cell. Rep. Phys. Sci. 2021, 2, 100350.
178. Tang, L.; Yang, Z.; Zhou, Z.; et al. A logic-gated modular nanovesicle enables programmable drug release for on-demand chemotherapy. Theranostics 2019, 9, 1358-68.
179. Jiang, C.; Zhao, Z.; East, A. K.; Bandyopadhyay, S.; Jiang, Z.; Chan, J. Logic-gated approach for targeted delivery and site-selective activation of photothermal agents in precision cancer treatment. Chem. Sci. 2025, 16, 5155-65.
180. Mishra, V.; Kumari, N.; Vyas, M.; Aljabali, A. A. A.; Chattaraj, A.; Mishra, Y. Advances in multimodal imaging techniques in nanomedicine: enhancing drug delivery precision. RSC. Adv. 2025, 15, 27187-209.
181. Saladino, G. M.; Mangarova, D. B.; Nernekli, K.; et al. Multimodal imaging approach to track theranostic nanoparticle accumulation in glioblastoma with magnetic resonance imaging and intravital microscopy. Nanoscale 2025, 17, 9986-95.
182. Ju, S.; Cho, H. Y. Biohybrid nanoparticle-based in situ monitoring of in vivo drug delivery. Biosensors 2023, 13, 1017.
183. Yang, Y.; Yue, S.; Qiao, Y.; et al. Activable multi-modal nanoprobes for imaging diagnosis and therapy of tumors. Front. Chem. 2020, 8, 572471.
184. Chen, Y.; Zhang, C.; Yu, Z.; Hu, K.; Zhou, T. Circumventing tumor immune evasion: coordinated immunotherapy via in situ tumor nanovaccines and local ablation. Chem. Eng. J. 2025, 523, 168636.
185. Parvin, N.; Joo, S. W.; Mandal, T. K. Biodegradable and stimuli-responsive nanomaterials for targeted drug delivery in autoimmune diseases. J. Funct. Biomater. 2025, 16, 24.
186. Zheng, C.; Li, M.; Ding, J. Challenges and opportunities of nanomedicines in clinical translation. Bio. Integration. 2021, 2, 57. https://bio-integration.org/10-15212-bioi-2021-0016/ (accessed 2026-04-24).
187. Han, Y.; Kim, D. H.; Pack, S. P. Nanomaterials in drug delivery: leveraging artificial intelligence and big data for predictive design. Int. J. Mol. Sci. 2025, 26, 11121.
188. Chakroborty, S.; Nath, N.; Sahoo, S.; et al. A review of emerging trends in nanomaterial-driven AI for biomedical applications. Nanoscale. Adv. 2025, 7, 3619-30.
189. DeRidder, L. B.; Hare, K. A.; Lopes, A.; et al. Closed-loop automated drug infusion regulator: a clinically translatable, closed-loop drug delivery system for personalized drug dosing. Med 2024, 5, 780-796.e10.
190. Paci, M. M.; Saha, T.; Djassemi, O.; et al. Smart closed-loop drug delivery systems. Nat. Rev. Bioeng. 2025, 3, 816-34.
